City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Donald Trump. The company has indicated that it is ...

NICE has said that four artificial intelligence technologies can be deployed by the NHS to detect fractures on X-rays in urgent care, while more evidence on their value is generated, but has limited ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three months after taking on the role. His departure – first reported by STAT and now ...

The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...